Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Group 1 - Tonix Pharmaceuticals is a clinical-stage biotechnology firm focused on developing TNX-102 SL, a compound aimed at improving sleep quality in fibromyalgia patients [1] - The FDA is currently reviewing TNX-102 SL, with a Prescription Drug User Fee Act (PDUFA) date set for August 15, 2025 [1] - The company aims to bridge the gap between scientific advancements and financial strategies in the healthcare sector, assisting clients in uncovering hidden value and assessing risks [1]